Innate Pharma: Brace yourselves… AZN is coming (back)!

BUY Coverage initiated, Fair Value EUR19 (+44%)
News published on September Tuesday 29, 2015
Share on

We are initiating coverage of the stock with a BUY recommendation and a Fair Value of EUR19. Innate Pharma is one of the rare companies to be developing a checkpoint inhibitor targeting the two sides of immunity (innate and adaptive) with IPH2201 and a potential biomarker. In our view, a new inflection point is approaching with the announcement of AstraZeneca’s development plan for this potential blockbuster. Even without taking into account this announcement, we deem the risk-reward to be attractive with a 12-month FV ranging between EUR15.5 and EUR22.  

For more information, please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities